The mRNA synthesis raw materials market is projected to grow from USD 1.8 billion in 2026 to USD 3.2 billion by 2036, at a CAGR of 5.9%. Nucleotides will dominate with a 37.0% market share, while vaccine production will lead the application segment with a 40.0% share.